Cerebral morphometry and clozapine treatment in schizophrenia.
Studies of brain morphology in schizophrenia may be informative about basic pathophysiologic processes, provide clinically useful indicators of treatment response, and lead to the identification of markers for selective treatment effects. This paper reviews findings from magnetic resonance imaging studies of patients with schizophrenia conducted at Hillside Hospital, with special attention to (1) findings that have helped distinguish patients who respond well to typical neuroleptics from those who have gone on to trials of clozapine, (2) the capacity of morphological measures to predict clozapine treatment response, and (3) the possibility that selective hypertrophy of striatal structure may be caused by chronic treatment with typical neuroleptics, but not by clozapine.
Department of Psychiatry Research, Hillside Hospital Division of Long Island Jewish Medical Center, Glen Oaks, NY 11004.
R M
RM
Bilder
H
H
Wu
M H
MH
Chakos
B
B
Bogerts
S
S
Pollack
J
J
Aronowitz
M
M
Ashtari
G
G
Degreef
J M
JM
Kane
J A
JA
Lieberman
D001284:Atrophy; D001479:Basal Ganglia / Q000033:anatomy & histology / Q000187:drug effects; D001921:Brain / Q000033:anatomy & histology* / Q000473:pathology; D003024:Clozapine / Q000627:therapeutic use*; D003342:Corpus Striatum / Q000033:anatomy & histology / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology
D003024:Clozapine